Targets › HBSAG
3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 4; Infectious disease; next expected readout Jul 2027.
Open in Phaseline: the race on HBSAG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Health Network, Toronto | Hepatitis B Immune Globulin Surface antigen (HBsAg) binding agent | HBSAG | Phase 4 | Hepatitis B Virus (HBV) | Aug 2027 |
| Rockefeller University | HepB mAb19 anti-HBV surface antigen (HBsAg) monoclonal antibody targeting the 'a' determinant | HBSAG | Phase 1 | Hepatitis b Virus | Jul 2027 |
| Aarhus University Hospital | HepB mAb19 Hepatitis B surface antigen (HBsAg) binding monoclonal antibody | HBSAG | Phase 1 | Hepatitis B; Hepatitis D, Chronic | Aug 2027 |
Hepatitis b Virus (1) Hepatitis B (1) Hepatitis D, Chronic (1) Hepatitis B Virus (HBV) (1)
protein or peptide (1), small molecule (1), mixed (1)
Rockefeller University (1) Aarhus University Hospital (1) University Health Network, Toronto (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.